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Abstract
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by
the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia
nigra pars compacta (SNpc). Chronic neuroinflammation is one of the hallmarks of PD pathophysiology. Post-
mortem analyses of human PD patients and experimental animal studies indicate that activation of glial cells and
increases in pro-inflammatory factor levels are common features of the PD brain. Chronic release of pro-
inflammatory cytokines by activated astrocytes and microglia leads to the exacerbation of DA neuron degeneration
in the SNpc. Besides, peripheral immune system is also implicated in the pathogenesis of PD. Infiltration and
accumulation of immune cells from the periphery are detected in and around the affected brain regions of PD
patients. Moreover, inflammatory processes have been suggested as promising interventional targets for PD and
even other neurodegenerative diseases. A better understanding of the role of inflammation in PD will provide new
insights into the pathological processes and help to establish effective therapeutic strategies. In this review, we will
summarize recent progresses in the neuroimmune aspects of PD and highlight the potential therapeutic
interventions targeting neuroinflammation.
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Introduction
Parkinson’s disease (PD) is an age-related neurodegen-
erative disorder characterized clinically by resting
tremor, slowness of movement, rigidity and postural
instability and pathologically by the progressive loss of
dopaminergic (DA) neurons in the substantia nigra pars
compacta (SNpc) [1–4]. Deposition of protein aggre-
gates containing α-synuclein (termed Lewy bodies) is
evident in multiple brain regions of advanced PD
patients [5]. The etiology of PD has not yet been fully
understood. Although a variety of possible pathogenetic
mechanisms have been proposed over the years, includ-
ing excessive release of oxygen free radicals during
enzymatic dopamine breakdown, impairment of mito-
chondrial function, loss of trophic support, abnormal
kinase activity, disruption of calcium homeostasis,
dysfunction of protein degradation and neuroinflamma-
tion, the pathogenesis of PD is still largely uncertain
[6–8]. However, emerging evidence indicates that
sustained inflammatory responses, T cell infiltration
and glial cell activation are common features of both
human PD patients and animal models of PD and play
vital roles in the degeneration of DA neurons [9, 10],
which suggests the possibility of developing potential
therapies for PD by targeting the inflammatory pro-
cesses. In this review, we will focus on the role of
inflammation in the progression of PD and the poten-
tial application of anti-inflammatory medications in the
treatment of this devastating disorder.
Microglia-mediated inflammation in PD
Microglia is one of the major cell types which are
involved in the inflammatory responses in the central
nervous system (CNS) [11]. In 1988, McGeer et al.
showed the presence of reactive microglia in the SNpc
of human post-mortem brain tissue, which is the
evidence revealed for the first time suggesting the
involvement of neuroinflammation in PD pathogenesis
[12]. Positron emission tomography (PET) studies also
indicate that there is pronounced activation of microglia
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in various regions of PD brain [13, 14]. Moreover, activa-
tion of microglia in the SNpc and striatum is profound in
various types of PD animal models [15–17]. Further
biochemical analysis reveals higher levels of pro-
inflammatory mediators including tumor necrosis factor-α
(TNF-α), interleukin-1β (IL-1β) and interferon-gamma
(IFN-γ) in the midbrain of PD patients. These data
strongly suggest the involvement of immune components
in PD pathogenesis.
Under physiological conditions, the quiescent state of
microglia is maintained by a variety of immunomodula-
tors, such as CX3CL1, CD200, CD22, CD47, CD95 and
neural cell adhesion molecule (NCAM), which are pro-
duced mainly by neuronal cells [18–26]. Interestingly,
the receptors for these molecules are almost exclusively
expressed by microglia in the CNS, indicating the crit-
ical role of neuron-microglia interactions in the regula-
tion of neuroinflamamtion [18–26]. For instance,
CX3CL1-CX3CR1 signaling negatively regulates micro-
glial activation and protects DA neurons from degener-
ation induced by neurotoxins [27, 28]. Deficiency of
CX3CL1 or CX3CR1 in vivo results in increased neuro-
toxicity induced by systemic lipopolysaccharide (LPS)
treatment and enhanced cell death of DA neurons in
the SNpc of animal PD models [28, 29]. Likewise, dys-
function of CD200-CD200R signaling also increases the
activation of microglia and exacerbates the degener-
ation of DA neurons in rat PD models [30, 31].
It has been proposed that activated microglia may be
beneficial to the host, at least in the early phase of neuro-
degeneration process [12, 32–34]. For instance, it has been
shown that suppression of Jmjd3, which is essential for
M2 microglia polarization, in the substantia nigra (SN) in
vivo dramatically causes microglial overactivation and ex-
acerbated dopamine (DA) neuron death in a PD animal
model [35], indicating a protective role of M2 microglia in
this process. However, long-term over-activation of micro-
glia in the PD brain significantly up-regulates the expres-
sion of a large group of pro-inflammatory cytokines
including TNF-α, IL-1β, interleukin-6 (IL-6) and IFN-γ,
which contribute to the acceleration of nigral DA neuron
degeneration [36, 37]. As the disease progresses, mole-
cules such as α-synuclein, ATP and metalloproteinase-3
(MMP-3) released from the degenerating DA neurons will
further enhance microglia activation, amplify the neuroin-
flammatory responses in the brain, and result in the de-
terioration of the neurodegenerative processes [11, 38]
forming a vicious cycle of neurodegeneration. Activated
microglia accumulate around the α-synuclein-positive ag-
gregates in many regions of PD brain [39]. These cells are
likely activated by over-produced [38, 40], mutants or mis-
folded α-synuclein leading to increases in the production
and release of the pro-inflammatory cytokines [38, 41, 42].
Thus, the neurotoxicity induced by excessive or misfolded
α-synuclein may be partially caused by microglia-
mediated inflammatory responses.
ATP, a purinergic neurotransmitter, is also able to ro-
bustly modulate various functions of microglia [43, 44].
The migration of microglia to the injured and inflamma-
tory areas is controlled by ATP released from the damaged
neurons and neighboring astrocytes [44]. In addition, ATP
binds to the P2Y receptor which is mainly expressed by
microglia in the brain and induces the production of high
levels of IL-1β, TNF-α and nitric oxide (NO) [45]. Another
protein produced by degenerating neurons is MMP-3
which also plays important roles in the regulation of the
activation states of microglia, at least in vitro. Overexpres-
sion of MMP-3 in microglia-neuron co-cultures induces
prominent activation of microglia and increased the
oxidative stress reaction. In contrast, MMP-3−/− mice
administrated with N-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) display attenuated nigrostriatal DA neur-
onal degeneration, microglial activation, and superoxide
generation [46]. These data support the notion that micro-
glia is a major player in neuroinflammation in the context
of PD pathogenesis and MMP-3 plays a pivotal role in
dopaminergic neuronal degeneration.
Microglia activation phenotypes in PD
Mounting evidence indicates that microglia has two
alternative activation phenotypes, termed the M1 (pro-
inflammatory) phenotype and the alternative M2 (anti-
inflammatory) phenotype. These different activation
statuses of microglia are characterized by secretion of
different arrays of cytokines [47]. It has been demon-
strated that LPS/IFN-γ treatment induces M1 activa-
tion, while IL-4/IL-13 treatment triggers M2 activation
in microglia. The classical M1 activation of microglia is
featured by the production of pro-inflammatory cyto-
kines, including TNF-α, IL-1β, IL-6, IL-12, and other
cytotoxic molecules such as superoxide, NO and react-
ive oxygen species (ROS), contributing to the amplifica-
tion of the pro-inflammatory responses during injuries
and infections. Conversely, M2 microglia plays an
immunosuppressive role by antagonizing the classic M1
microglia and promoting tissue repair. The M2 micro-
glia produces a variety of cytokines with anti-
inflammatory property, such as IL-4, IL-13, IL-10, and
TGF-β. The different activation forms of microglia can
be distinguished by their characteristic gene expression
pattern. For example, Arg1, FIZZ1 (also known as
RELM-α), Chi3l3 (also known as YM1) and CD206
were expressed in mouse M2 phase microglia [48]. Ex-
pression of Arg1, FIZZ1 and Chi3l3 may be regulated
by cytokines, since their levels are significantly in-
creased in primary cultured microglia or the striatal
and frontal cortical regions of mouse brain following
IL-4 stimulation [49].
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What factors affect M1/M2 microglia phenotype in the
context of PD? Mis-folded proteins and environmental
toxins induce the activation of microglia toward M1
phenotype in PD animal models [38, 50, 51]. Chronic
MPTP administration leads to progressive reduction of
CD206 expression, which suggests the down-regulation of
M2 phase activation of microglia in the progression of PD
[47]. Conversely, IL-4 treatment up-regulates microglial
expression of histone H3K27me3 demethylase (Jmjd3)
which is involved in the regulation of epigenetic modifica-
tion of chromosomes and contributes to various human
diseases. Expression levels of M2 marker genes, such as
Arg1 and CD206, are significantly down-regulated after
Jmjd3 knockdown in N9 microglia cell line, indicating the
essential role of Jmjd3 for M2 microglia polarization.
Knockdown of Jmjd3 in vivo exacerbates the DA neuron
loss in the SNpc of MPTP-induced mouse PD model by
revoking M2 activation of microglia [35].
Conditioned medium (CM) from M1 phase N9 micro-
glia results in increased death of DA neurons, whereas
CM mixture from both M1 and M2 cells reverses the
neurotoxicity elicited by the M1-CM [35]. Previous in-
vestigations indicated that a majority of the activated
microglia express M2 associated genes at the early stages
following injury in various models. M1 signature genes,
however, gradually become predominant in later stages
[32]. These interesting observations suggest that it is im-
portant to balance different microglia activation pheno-
types in PD (Fig. 1). It appears to be a promising
strategy to intervene the progression of PD by manipu-
lating the transition of microglia activation statuses.
Even though current data suggest differential role of M1
and M2 in the pathogenesis of PD in its animal models,
similar results from patients are lacking. Future work
should warrant research in this aspect.
Astrocyte-mediated neuroinflammation in PD
A great body of studies show that astrocytes also play
vital roles in the neuroinflammatory processes in PD.
Like microglia, astrocytes respond to the inflammatory
stimulations such as LPS, IL-1β and TNF-α by produ-
cing pro-inflammatory cytokines both in vitro and in
vivo [11, 52]. Reactive astrogliosis characterized by the
increased expression levels of glial fibrillary acidic pro-
tein (GFAP) and hypertrophy of cell body and cell exten-
sions have been reported in various PD animal models.
Fig. 1 Diagrammatic representation of inflammatory mechanisms involved in PD pathogenesis. Microglia become activated M1 phenotype in PD
under pathological conditions such as protein aggregation, gene mutations, environmental factors and cytokines released from infiltrated T cells.
The pro-inflammatory mediators from M1 microglia activate astrocytes leading to elevated production of proinflammatory factors, nitric oxide
and superoxide radical, contributing to degeneration of DA neurons. The molecules released from degenerative DA neurons can further cause
activation of glia and enhanced inflammatory response. At certain stage of PD, subpopulation of microglia may become activated M2
phenotype releasing anti-inflammatory factors, including TGF-β, and exert a neuroprotective effect in PD
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Importantly, astrogliosis also exists in the affected brain
regions of patients with PD, indicating the possible in-
volvement of astrocytes in the immune processes in PD
[53].
It has been observed that astrocytic responses are
relatively slower than microglial activation after stimula-
tions. Microglia may initiate the inflammatory responses
after immune stimulations such as LPS treatment and α-
synuclein aggregation. Astrocytes are then activated by a
variety of molecules including pro-inflammatory media-
tors released from activated microglia and these immu-
nosignals are further amplified by astrocytes [11].
Uncontrolled neuroinflammation caused by the synergic
activation of microglia and astroyctes ultimately contrib-
utes to the enhanced death of DA neurons in the SNpc
during neurodegeneration [11, 54]. The expression levels
of TNF-α and IL-6 of primary cultured astrocytes are in-
creased significantly after α-synuclein treatment in vitro
[55]. Specific overexpression of mutant α-synuclein in
astrocytes causes widespread astrogliosis, microglial acti-
vation and degeneration of DA neurons and motor neu-
rons in mice [56].
One of the long-standing questions in PD research is
how the neuroinflammation is developed and the roles
of astrocytes in this process. Human post-mortem and
animal experimental results suggest a progressive decline
of the dopaminergic neuronal system with age [57].
Whether the reduction of Drd2 in aging brain has sig-
nificant impact on brain function and ultimately contrib-
ute to the development of early/mid-stage PD remains
poorly understood. This reduction primarily reflects the
changes in neuronal cells. In sharp contrast, the contri-
bution from glial Drd2 in overall levels is minor. Indeed,
our own studies have revealed that astrocytic Drd2 is of
very low abundance in overall levels of Drd2 in the stri-
atal tissue [58]. Given that astroglial and microglial cells
are the ‘sensors’ in the brain which constantly monitor
brain activities, it is likely that glial Drd2 is more vulner-
able to microenvironment changes, despite that glial
Drd2 abundance is very low in the brain. Nevertheless,
the biological consequence of glial Drd2 loss may be sig-
nificant. Ablation of astrocytic Drd2 causes dramatic re-
duction of anti-inflammation protein alphaB-crystallin in
the CNS [58, 59]. Thus, glial Drd2 may be an important
player in the maintenance of immune homeostasis
(Fig. 1). It is plausible that down-regulation of Drd2, pre-
sumably including those in glial cells, in aging brain
compromise the immune homeostasis contributing to
PD pathogenesis. Future studies may be required to de-
velop new technology that can specifically label and
visualize glial dopamine receptors in aging and PD
brain.
The idea that Drd2 plays important roles in the modula-
tion of neuroinflammation is supported by a recent study
in which Drd2 activation by Drd2 agonists quinpirole and
ropinirole reduces expression levels of IL-1β and
monocyte chemoattractant protein-1 as well as microglia/
macrophages activation in experimental intracerebral
hemorrhage brain injury model [60]. These results further
suggest the anti-inflammatory effects of Drd2 in certain
CNS disorders.
PD-associated genes and neuroinflammation
Increasing evidence indicates that some PD-associated
genes are involved in the regulation of immune responses
of microglia and astrocytes in the CNS. One of such genes
is α-synuclein (SCNA), the missense mutations of which
results in a familial form of PD [61]. Abnormal accumula-
tion of α-synuclein in neuronal cytoplasm and neurites is
one of the pathological hallmarks of PD [62]. Wild-type or
pathogenic forms of α-synuclein induces pronounced
microglial activation in vitro [63]. Furthermore, oligomers
of α-synuclein could elicit microglia responses through
the activation of toll-like receptor 2 (TLR2)-mediated
signaling [64]. In α-synuclein transgenic mice, there is
prominent activation of microglia and upregulation of
TLRs in the brainstem and SNpc [65, 66].
In the last several years, the common variations in
leucine-rich repeat kinase 2 (LRRK2) gene have been
identified as risk factors of both familial and sporadic
PD [67–70]. Inflammatory stimuli such as LPS could
drastically enhance the expression levels of LRRK2 in
primary cultured microglia [71], while knockdown of
LRRK2 reduces LPS-induced TNF-α and iNOS produc-
tion and also decreases the activation of nuclear factor κ
B (NF-κB) transcriptional activity in microglia [72].
Moreover, the expression levels of pro-inflammatory cy-
tokines are higher in microglia isolated from LPS-
challenged transgenic mice overexpressing R1441G mu-
tation of LRRK2 than in microglia from LPS-treated WT
mice [73]. These data suggest that LRRK2 regulates
microglia activation thus might contribute to the pro-
gression of PD through neuroinflammatory pathways.
Of note, Lrrk2 has been shown to play crucial roles in
periphery inflammation. LRRK2 is relatively abundant in
peripheral blood mononuclear cells and macrophages in
the immune system. Expression levels of LRRK2 are sig-
nificantly increased in the process of THP-1 monocyte-
to-macrophage differentiation following IFN-γ treatment
[74, 75]. LRRK2 deficiency results in enhanced suscepti-
bility to experimental colitis in mice [76], indicating the
important role of LRRK2 in periphery inflammation and
its potential association with PD.
Parkin is another PD-associated gene which encodes
an E3-ubiquitin ligase. Mutations in parkin are the most
common causes of recessively inherited PD [77]. Sys-
temic LPS treatment induces more prominent degener-
ation of DA neurons in the SNpc of parkin knockout
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mice, comparing with littermate controls [78]. Aged par-
kin knockout mice display increased astrogliosis in the
striatum and aberrant microglial activation in the mid-
brain [79]. Co-culture of microglia from parkin knock-
out mice and wild-type neurons increase sneuronal
vulnerability to rotenone toxicity [80], suggesting that
parkin-null microglia produce and release soluble factors
that are detrimental to neuronal cells. Indeed, these
microglia express higher levels of pro-inflammatory
cytokines such as TNF-α, IL-6 and iNOS after LPS chal-
lenge [81], implicating that parkin plays an important
role in the regulation of PD-associated inflammation.
Missense mutations in the PTEN-induced putative
kinase1 (PINK1) gene cause the early-onset, recessively
inherited form of PD [82]. Under pathological conditions,
PINK1 directly phosphorylates parkin to enhance its activ-
ity and causes mitochondria damages [83]. PINK1 is also
involved in the regulation of inflammatory cytokine pro-
duction. Under basal condition and following systemic
LPS treatment, mice null for PINK1 produce higher levels
of pro-inflammatory cytokines including IL-1β, IL-12 and
TNF-α [84, 85]. The underlying molecular mechanisms of
PINK1’s effect remain elusive. PINK1 may regulate IL-1β-
mediated NF-κB activity through interacting with IL-1
receptor-associated kinase 1 (IRAK1) and toll-interacting
protein (Tollip) [86].
It has been shown that DJ-1, one of PD genes, is
mainly expressed in astrocytes and microglia in human
brain and the expression levels of DJ-1 are strongly up-
regulated in reactive astrocytes in PD patients [87]. As-
trocytes from DJ-1 knockout mice produce higher levels
of cyclooxygenase-2 (COX2) and IL-6 following LPS
treatment [4]. Primary neurons plated on DJ-1-null as-
trocytes shows severe apoptosis following LPS treatment,
which indicates that loss of DJ-1 might contribute to PD
pathogenesis by astrocyte-mediated neuroinflammatory
response [4]. Likewise, microglia with DJ-1 knockdown
also exhibits hyper-responsiveness to LPS [88]. Taken to-
gether, it is highly likely that mutation, down-regulation
or overexpression of PD associated genes perturb the ex-
pression of pro-inflammatory cytokines in glial cells after
LPS treatment. The question that how PD genes regulate
inflammatory responses in PD should be addressed in
the future.
Peripheral immune cell-mediated inflammation in PD
Under physiological conditions, the peripheral immune
cells such as T- and B-lymphocytes are hardly detectable
in the CNS. Following infections or tissue injuries, blood
monocytes and tissue-resident macrophages are quickly
activated and secret an array of inflammatory cytokines
like IL-1β, TNF-α and IL-6 as well as chemokines. These
cytokines and chemokines could enter the brain and
stimulate microglia to initiate the neuroinflammatory
reactions [89]. The CNS has been considered as im-
munologically privileged because of the existence of
blood brain barrier (BBB). It is known that the neurovas-
cular unit is formed by tight junctions between endothe-
lial cells and the surrounding components of the CNS,
including pericytes, astrocytes and the basement mem-
brane. BBB limits the entrance of pathogens and periph-
eral immune cells into the brain parenchyma. BBB
breakdown leads to increased infiltration of peripheral
immune cells into the CNS, which has been identified as
one of the major contributing factors for neurodegenera-
tive diseases including PD [90, 91]. There are dramatic-
ally morphological changes of endothelial cells in the
SNpc of PD brain, suggesting the possible dysfunction of
BBB in the pathological processes of PD [91–93]. Several
studies show a strong correlation between the BBB dis-
ruption and loss of DA neurons in mice by intranigral
injection of vascular endothelial growth factor (VEGF)
which is a potent inducer of BBB damages [94, 95]. Fur-
thermore, the expression levels of VEGF are drastically
increased in both PD patients and the MPTP-induced
mouse PD model [94].
The number of activated microglia and infiltrated B
and T-lymphocytes is significantly increased in the
SNpc of AAV-mediated α-synuclein overexpressing
mice. Moreover, nitrated α-synuclein can get through
the BBB, enter cervical lymph node causing activation
of T-lymphocytes and increases in the expression of
the class II major histocompatibility complex in
MPTP-treated mice. Transplantation of T cells from
mice immunized with nitrated α-synuclein into the
brain significantly exacerbates the neuroinflammatory
responses and degeneration of DA neurons. Con-
versely, mice deficient in T- and B-lymphocytes are
more resistant to the neurotoxicity caused by MPTP
intoxication [16, 96]. Furthermore, MPTP-induced
neurotoxicity is markedly attenuated in the SNpc of
CD4−/− mice. Peripheral inflammation caused by
ulcerative colitis increase LPS-induced DA neuron
degeneration, microglial activation, production of pro-
inflammatory cytokines and permeability of the BBB
[97]. These data indicate that there is a close relation-
ship between the peripheral immune system and the
progression of PD. A better understanding of the rela-
tionship between the CNS and immune system and
the molecular mechanisms underlying their crosstalk
may help to further clarify the pathological processes
of PD.
It has been reported that systemic infection could con-
tribute to the etiology and the progress of PD [98, 99].
Indeed, the main causes of death in PD patients are re-
spiratory infections [98]. Gastrointestinal infections
could lead to a worsening of PD [100, 101]. Moreover,
infection of helicobacter pylori (HP), a bacterium found
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on the luminal surface of the gastric epithelium, is asso-
ciated with clinical diagnosis and worse severity of
motor function in PD patients [102, 103]. These data in-
dicate a link between systemic infection and PD. It
would be very interesting to see whether control of sys-
temic infections helps to reduce the exacerbation of PD
symptoms and delay the disease progression.
Anti-inflammatory therapies in PD
Given the important roles of neuroinflammation in the
initiation and progression of PD, it is desirable to
develop intervening therapies for this devastating dis-
order by targeting the inflammatory pathways mediated
by activated glial cells. For example, soluble TNF-α is
known to contribute to the progressive degeneration of
DA neurons in rodents induced by stereotactic injec-
tion of 6-hydroxydopamine (6-OHDA) or LPS. Overex-
pression of dominant-negative TNF-α specifically
inhibits TNF signaling in the SNpc and attenuates acti-
vation of microglia, thereby reducing loss of DA neu-
rons and improving locomotor ability in 6-OHDA-
induced rat PD model [104, 105].
Minocycline is a semi-synthetic, second-generation
tetracycline analog, which, as a lipophilic molecule, can
easily get through the BBB and has been reported to
have anti-inflammatory and neuroprotective properties
in multiple inflammation-related neurological diseases
[106, 107]. Minocycline treatment effectively protects
DA neurons from degeneration and decreases glial cell
activation in the SNpc of LPS and 6-OHDA challenged
mice [108, 109]. Administration of minocycline also
blocks MPTP-induced neurotoxicity of DA neurons in
vivo by directly or indirectly inhibiting the phosphoryl-
ation of p38 MAPK, which is a key regulator of the
expression of inflammatory genes [110]. It is often disap-
pointing to note that, although there are many encour-
aging studies, the therapeutic potential of minocycline in
PD is still controversial. In addition to beneficial effect
of mincycline, it is also found to exacerbate the loss of
DA neurons and behavior deficits in MPTP-induced ro-
dent and non-human primate models [111]. The reason
for these discrepancies is not clear. One of the probabil-
ities is that it may due to the different drug dosages and
durations used in different studies.
Besides minocycline, some other compounds with anti-
inflammatory properties also show significant protective
functions for DA neuron in PD models. Glucocorticoids
are well known for their broad ranges of anti-
inflammatory effects and have been widely used in clinical
studies for brain inflammation. Glucocorticoid receptor
expressed on microglia is found to regulate the expression
of the transcription factors such as NF-κB and activator
protein-1 (AP-1) which are key regulators of inflammatory
gene expression [112, 113]. Administration of the
synthetic steroid dexamethasone shows a protective effect
for DA neurons and decreased the activation of glial cells
in the SNpc of MPTP- or LPS-treated mice [112, 114].
Moreover, opioid antagonist naloxone has been shown to
inhibit LPS-induced activation of microglia and expression
of pro-inflammatory cytokines in vitro, attenuating neur-
onal loss. The compound dramatically reverses the acute
dystonia and parkinsonism following general anaesthesia
[115, 116].
Several non-steroidal anti-inflammatory drugs
(NSAIDS), such as aspirin, salicylic acid (SA), ibuprofen
and celecoxib, have also been shown to have protective
effects on DA neurons in PD [117–120]. Aspirin is a po-
tent inhibitor of COX2, which plays important roles in
the processes of neuroinflammation and neuronal de-
generation [121]. Aspirin promotes the resolution of in-
flammation [122] and prevents dopamine depletion in
the striatum in MPTP-induced mouse and 6-OHDA-
induced rat PD models [117]. SA is a metabolite product
of aspirin, which is widely used for the treatment of
myocardial infarction, cardiovascular diseases [118]. SA
administration in MPTP mice alleviates the neurotoxin-
induced behavioral impairments as well as dopamine de-
pletion [118, 123]. Similarly, ibuprofen and celecoxib
also show protective roles for DA neurons in MPTP-
and 6-OHDA-induced PD models [119, 120]. Long-term
use of NSAIDs, especially the use of ibuprofen,
decreased PD risk by 21 %, suggesting high therapeutic
potentials of NSAIDs for PD [120, 124, 125].
Concluding remarks
Animal experiments and clinical studies have generated
an array of evidence supporting the involvement of in-
flammation in the progression of PD (Fig. 1). However,
the precise role of inflammation in PD is still not fully
understood. Moreover, the inflammatory responses in PD
refer to both glial activation and peripheral immune cell
infiltration, but the relationship between these two differ-
ent inflammatory pathways is still unclear. These issues
significantly hamper the development of PD-modifying
therapeutics by targeting inflammatory pathways. More-
over, the different forms of microglia activation further
increase the difficulty and complexity of manipulation of
microglial responses in PD. A better understanding of
how these two activated phenotypes of microglia contrib-
ute to PD progression may provide a basis for future drug
discoveries. So far, many candidate drugs targeting inflam-
mation in PD have been developed and tested. Although
some of them have been reported to attenuate the behav-
ior deficits and loss of DA neuron in PD animal models,
the clinical studies of these candidates only show moder-
ate effects. Future studies should focus on identifying
more specific drug targets by extending the understanding
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of fundamental processes of inflammation at different
stages of the disease progression.
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